糖基化是美拉德反应的一部分,在食品和生物过程中以非酶促方式发生。N-糖基化的选择性基于单糖与芳香胺(包括芳香氨基酸)的反应性以及使用液相色谱测量的分子相互作用 (MI) 程度进行分析。此外,使用 X 射线晶体学和/或 NMR 确定反应产物的化学结构。使用不同构象的优化能量值在计算机中估计可能的反应产物。使用模型相的计算机分析计算氨基和糖类的 MI 能量值。具有较大 MI 值的糖类容易产生稳定的 N-糖苷晶体。葡萄糖(一种能量糖)的反应速度很慢,它很容易产生 Amadori 化合物。芳香胺与糖类反应性的研究、单糖在色谱中氨基相保留的测量以及 N-糖苷的合成以确定其结构将为候选药物的修饰提供有关选择性糖基化的有用信息以提高它们的水溶性。
The infrared spectra of N-substituted glycosylamines
作者:G. P. Ellis
DOI:10.1039/j29660000572
日期:——
The infraredspectra of a number of N-substituted glycosylamines have been examined over the ranges 1800–1500 and 960–700 cm.–1; the spectra indicate the presence of a pyranose ring. Comparison of the spectra of the two isomeric N-phenyl-D-ribosylamines with those of methyl β-D-ribopyranoside and methyl and benzyl β-D-ribofuranoside, suggests that the ribosylamines are pyranose but a furanose structure
Inouye et al., Nippon Nogeikagaku Kaishi, 1951, vol. 25, p. 59,61
作者:Inouye et al.
DOI:——
日期:——
Synthesis of N-(substituted phenyl)-D-xylopyranosylamines as potential modifiers of the formation of glycosaminoglycans
作者:Lin Wang、Charles A. Maniglia、Sharon L. Mella、Alan C. Sartorelli
DOI:10.1021/jm00359a002
日期:1983.5
N-(Substituted-phenyl)-D-xylopyranosylamines and their O-peracetyl derivatives have been synthesized and tested for their ability (a) to inhibit the replication of cultured B16 melanoma cells and (b) to modify the synthesis of glycosaminoglycans by these neoplastic cells. The most cytotoxic compound synthesized was N-(p-methoxyphenyl)-D-xylopyranosylamine (6), which produced 50% inhibition of cellular proliferation at a concentration of 2 microM; a number of other compounds were relatively cytotoxic, causing 50% inhibition of cell replication at levels of 12 to 25 microM. Several of the synthesized xylosides appeared to be capable of serving as artificial initiators of glycosaminoglycan synthesis, with the most active agents causing approximately 2- to 4-fold increases in the incorporation of [35S]sulfate into the glycosaminoglycans of B16 melanoma cells excreted into the culture medium.
D-Xylopyranoside series compounds and therapeutical compositions containing same